Enveric Biosciences, Inc. - ENVB
About Gravity Analytica
Recent News
- 09.17.2025 - Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds
- 09.17.2025 - Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery
- 09.16.2025 - Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission
- 09.03.2025 - Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference
- 09.02.2025 - Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA
- 08.28.2025 - AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush? [Microdose]
- 08.28.2025 - Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications
- 08.19.2025 - Reimagining Psychedelics: Mental Wellness Without the Roadblocks [Pharmaceutical Online]
- 08.18.2025 - Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets [Microdose]
- 08.14.2025 - The Future Of Psychedelic-Inspired Therapeutics: No-Trip Neuroplastogens [Life Science Leader]